IN8BIO, Inc.
INAB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001740279
No open-market purchases or sales by IN8BIO, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $5.35M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding IN8BIO, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 0 | 13 | +13 |
| Shares | 0 | 1.77M | +1.77M |
| Value | $0 | $12.2M | +$12.2M |
New holders (13)
Institutions that held IN8BIO, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Capital World Investors | 800,000 | $5.52M | 0.00% |
| Nantahala Capital Management, LLC | 375,000 | $2.57M | 0.15% |
| B. Riley Financial, Inc. | 257,378 | $1.76M | 0.22% |
| Vanguard Group Inc | 113,100 | $775.0K | 0.00% |
| Voss Capital, LLC | 80,727 | $555.0K | 0.23% |
| Tudor Investment Corp Et Al | 63,287 | $434.0K | 0.01% |
| Rock Creek Group, LP | 42,279 | $292.0K | 0.05% |
| Millennium Management LLC | 25,340 | $175.0K | 0.00% |
| BlackRock Inc. | 9,311 | $64.0K | 0.00% |
| UBS Group AG | 3,435 | $24.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 2,899 | $20.0K | 0.00% |
| Morgan Stanley | 200 | $1.00K | 0.00% |
| Wells Fargo & Company | 24 | $0 | 0.00% |
Sold out (0)
Institutions that held IN8BIO, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
None.